PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Dopamine - Market size and forecast 2018-2023 Anticholinergic agents - Market size and forecast 2018-2023 Tricyclic antidepressants - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AbbVie Inc. Acorda Therapeutics Inc. Biogen Inc. Bristol-Myers Squibb Co. Merck & Co. Inc. PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global progressive supranuclear palsy therapeutics market pipeline: Overview Exhibit 18: Global progressive supranuclear palsy therapeutics market pipeline: Snapshot Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Dopamine - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Dopamine - Year-over-year growth 2019-2023 (%) Exhibit 23: Anticholinergic agents - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Anticholinergic agents - Year-over-year growth 2019-2023 (%) Exhibit 25: Tricyclic antidepressants - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Tricyclic antidepressants - Year-over-year growth 2019-2023 (%) Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Others - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Asia - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 43: ROW - Year-over-year growth 2019-2023 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Global prevalence of geriatric population Exhibit 48: Impact of drivers and challenges Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: AbbVie Inc. - Vendor overview Exhibit 55: AbbVie Inc. - Business segments Exhibit 56: AbbVie Inc. - Organizational developments Exhibit 57: AbbVie Inc. - Geographic focus Exhibit 58: AbbVie Inc. - Key offerings Exhibit 59: AbbVie Inc. - Key customers Exhibit 60: Acorda Therapeutics Inc. - Vendor overview Exhibit 61: Acorda Therapeutics Inc. - Business segments Exhibit 62: Acorda Therapeutics Inc. - Organizational developments Exhibit 63: Acorda Therapeutics Inc. - Key offerings Exhibit 64: Acorda Therapeutics Inc. - Key customers Exhibit 65: Biogen Inc. - Vendor overview Exhibit 66: Biogen Inc. - Business segments Exhibit 67: Biogen Inc. - Organizational developments Exhibit 68: Biogen Inc. - Geographic focus Exhibit 69: Biogen Inc. - Key offerings Exhibit 70: Biogen Inc. - Key customers Exhibit 71: Bristol-Myers Squibb Co. - Vendor overview Exhibit 72: Bristol-Myers Squibb Co. - Business segments Exhibit 73: Bristol-Myers Squibb Co. - Organizational developments Exhibit 74: Bristol-Myers Squibb Co. - Geographic focus Exhibit 75: Bristol-Myers Squibb Co. - Key offerings Exhibit 76: Bristol-Myers Squibb Co. - Key customers Exhibit 77: Merck & Co. Inc. - Vendor overview Exhibit 78: Merck & Co. Inc. - Business segments Exhibit 79: Merck & Co. Inc. - Organizational developments Exhibit 80: Merck & Co. Inc. - Geographic focus Exhibit 81: Merck & Co. Inc. - Segment focus Exhibit 82: Merck & Co. Inc. - Key offerings Exhibit 83: Merck & Co. Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

AbbVie Inc. Acorda Therapeutics Inc. Biogen Inc. Bristol-Myers Squibb Co. Merck & Co. Inc.